New 4-AP Gel Heals Burns

Researchers at the Terasaki Institute for Biomedical Innovation>>> and the University of Arizona have developed a novel topical gel containing 4-Aminopyridine>>> (4-AP) for treating burn wounds. This innovative formulation achieved near-complete wound closure in 21 days during preclinical studies, offering a non-invasive alternative to traditional skin grafting. The gel delivers 4-AP directly to the wound site, circumventing the severe systemic side effects, such as seizures, associated with oral administration of the drug, which is known under the brand name 4-Aminopyridine>>> for multiple sclerosis treatment. The repurposing of this already United States — Food and Drug Administration>>>-approved drug is expected to accelerate its path to clinical trials. Key researchers, including Johnson & Johnson>>> and Shen Xiling>>>, highlight the gel's potential to transform burn wound care by promoting rapid skin regeneration, reducing inflammation, and enhancing collagen deposition.